Multiple Positive Catalysts Converge: Are Innovative Drugs Still the Focus for the Fourth Quarter?

Deep News

Sep 29

Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.

Is innovative drugs still the key theme to watch in the fourth quarter?

Full-chain positioning in innovative drugs, pay attention to T+0 trading tools.

Hong Kong Stock Connect Innovative Drug ETF Huabao #520880 offers 100% exposure to innovative drug R&D companies.

Hong Kong Stock Connect Healthcare ETF Huabao #159137 has over 50% CXO allocation.

MACD golden cross signals have formed, and these stocks are showing strong gains.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1110462263"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110462263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110462263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110462263","market":"fut","top_or_hot":-1,"title":"Multiple Positive Catalysts Converge: Are Innovative Drugs Still the Focus for the Fourth Quarter?","media":"Deep News","content":"<p>Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.<br><br>Is innovative drugs still the key theme to watch in the fourth quarter?<br><br>Full-chain positioning in innovative drugs, pay attention to T+0 trading tools.<br><br>Hong Kong Stock Connect Innovative Drug ETF Huabao #520880 offers 100% exposure to innovative drug R&D companies.<br><br>Hong Kong Stock Connect Healthcare ETF Huabao #159137 has over 50% CXO allocation.<br><br>MACD golden cross signals have formed, and these stocks are showing strong gains.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Multiple Positive Catalysts Converge: Are Innovative Drugs Still the Focus for the Fourth Quarter?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMultiple Positive Catalysts Converge: Are Innovative Drugs Still the Focus for the Fourth Quarter?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-29 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.<br><br>Is innovative drugs still the key theme to watch in the fourth quarter?<br><br>Full-chain positioning in innovative drugs, pay attention to T+0 trading tools.<br><br>Hong Kong Stock Connect Innovative Drug ETF Huabao #520880 offers 100% exposure to innovative drug R&D companies.<br><br>Hong Kong Stock Connect Healthcare ETF Huabao #159137 has over 50% CXO allocation.<br><br>MACD golden cross signals have formed, and these stocks are showing strong gains.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1110462263","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110462263","pubTimestamp":1790680230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.Is innovative drugs still the key theme to watch in the fourth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1574":"生物医药B类股","BK1161":"生物科技","LNGR":"Global X Longevity Thematic ETF","06978":"永泰生物-B","MEDX":"HORIZON KINETICS MEDICAL ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"多重利好催化剂汇聚：四季度创新药仍是重点？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"IBBQ":1,"MEDX":1,"LNGR":1},"content_text":"Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.Is innovative drugs still the key theme to watch in the fourth quarter?Full-chain positioning in innovative drugs, pay attention to T+0 trading tools.Hong Kong Stock Connect Innovative Drug ETF Huabao #520880 offers 100% exposure to innovative drug R&D companies.Hong Kong Stock Connect Healthcare ETF Huabao #159137 has over 50% CXO allocation.MACD golden cross signals have formed, and these stocks are showing strong gains.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}